Protein kinase C (PKC)e, a member of the novel PKC family, has key roles in mitogenesis and survival in normal and cancer cells. PKCe is frequently overexpressed in epithelial cancers, particularly in lung cancer. Using a short-hairpin RNA approach, here we established that PKCe is required for non-small cell lung carcinoma (NSCLC) growth in vitro as well as tumor growth when inoculated into athymic mice. Moreover, sustained delivery of a PKCe-selective inhibitor peptide, eV1-2, reduced xenograft growth in mice. Both RNA interference depletion and pharmacological inhibition of PKCe caused a marked elevation in the number of apoptotic cells in NSCLC tumors. PKCe-depleted NSCLC cells show elevated expression of pro-apoptotic proteins of the Bcl-2 family, caspase recruitment domain-containing proteins and tumor necrosis factor ligands/receptor superfamily members. Moreover, a Gene Set Enrichment Analysis revealed that a vast majority of the genes changed in PKCe-depleted cells were also deregulated in human NSCLC. Our results strongly suggest that PKCe is required for NSCLC cell survival and maintenance of NSCLC tumor growth. Therefore, PKCe may represent an attractive therapeutic target for NSCLC.
Introduction
Protein kinase C (PKC) isozymes comprise three classes of serine-threonine kinases ('classical' cPKCa, b, g, 'novel' nPKCs d, e, Z, y, and 'atypical' aPKCz and i/l) that have important roles in the control of cellular growth, survival, differentiation and transformation. Their cooperation with oncogenic stimuli, such as Ras, Myc and Fos, is well established (Hsiao et al., 1989; Barr et al., 1991; Han et al., 1995) . Despite the extensive knowledge on PKC signaling, there are still major gaps in our understanding of the striking functional specificity displayed by PKC isozymes. Depending on the cellular context, individual members of the diacylglycerol (DAG)/phorbol ester regulated cPKC and nPKC classes that modulate cellular responses either in cooperative or antagonistic manners. Studies have shown that PKCa and PKCd generally inhibit cell cycle progression or promote apoptotic and senescent responses, whereas PKCe mediates mitogenic responses (Black, 2000; Brodie and Blumberg, 2003; Nakagawa et al., 2005; Slupsky et al., 2007; Oliva et al., 2008; Caino et al., 2009) . In addition, activation of PKCe inhibits apoptotic responses triggered by a number of stimuli through both Akt-dependent and Akt-independent mechanisms (McJilton et al., 2003; Okhrimenko et al., 2005; Lu et al., 2006; Basu and Sivaprasad, 2007) . The diversity and heterogeneity in PKC isozyme function in distinct cell types may largely explain the limited therapeutic success of PKC inhibitors, which in most cases fail to discriminate between PKC isozymes.
The expression of PKC isozymes and their effectors is altered in human cancer. One of the most frequent alterations in tumors of epithelial origin is the overexpression of PKCe, particularly in lung, prostate and breast cancer. PKCe upregulation in tumors was defined as a prognostic marker for recurrence and patient survival (Griner and Kazanietz, 2007; Gorin and Pan, 2009) . Ectopic expression of PKCe in non-transformed epithelial cells leads to either growth advantage or a transformed phenotype (Mischak et al., 1993; Perletti et al., 1996) . A recent study revealed that transgenic overexpression of PKCe in the mouse prostate confers a preneoplastic phenotype (Benavides et al., 2011) . In the mouse skin, transgenic overexpression of PKCe leads to metastatic squamous carcinoma (Jansen et al., 2001) . Thus, despite cell type differences, it became clear that PKCe may have prominent roles in cancer initiation and progression (Gorin and Pan, 2009 ).
Lung cancer is one of the malignancies in which the role of PKC isozymes is still poorly understood. Studies from our laboratory revealed that PKCa and PKCd promote anti-mitogenic responses in non-small cell lung carcinoma (NSCLC) cells (Nakagawa et al., 2005; Oliva et al., 2008; Caino et al., 2009) . A study by Xiao and coworkers showed that expression of a dominant-negative PKCe mutant inhibits the progression of NSCLC cells through the cell cycle, suggesting that PKCe may have an important role in lung cancer development (Bae et al., 2007) . Moreover, PKCe inhibition resulted in a significant amplification of the cytotoxic activity of TRAIL in A549 cells and increased their apoptotic responsiveness (Felber et al., 2007) . Notably, >90% of human NSCLC tumors display elevated PKCe levels (Bae et al., 2007) . Several oncogenic stimuli implicated in lung cancer development, including the epidermal growth factor (EGFR) or K-Ras, signal through the second messenger DAG, a key step for PKCe activation (Toker, 1998; Parker and Murray-Rust, 2004) . It is therefore conceivable that PKCe has a role in the maintenance of the tumorigenic phenotype in lung cancer.
In this study, we present strong evidence that PKCe is required for the growth of NSCLC cells in vitro and tumorigenicity in nude mice. Moreover, we identified novel apoptosis-related transcriptional targets for PKCe that correlate with disease status in NSCLC.
Results and discussion
PKCe depletion impairs anchorage-dependent and anchorage-independent NSCLC cell growth Overexpression of PKCe, a member of the novel PKC family, is a hallmark of human epithelial cancers particularly in NSCLC tumors (Bae et al., 2007; Griner and Kazanietz, 2007) . We therefore speculated that this kinase has a role in the maintenance of the malignant phenotype in NSCLC cells. Analysis of PKCe expression in four different human NSCLC cells (H358, A549, H441 and H322) revealed a remarkable overexpression of PKCe relative to immortalized non-tumorigenic (HBEC3) cells (Figure 1a ), which fits with observations in human lung cancer specimens. To establish a role of PKCe in growth and tumorigenesis, we used a RNA interference silencing approach. Each of the four NSCLC cell lines was infected with PKCe shorthairpin RNA (shRNA) lentiviruses or a non-target shRNA lentivirus and stable pools selected with puromycin. Two different sequences (e#1 and e#2) were used in all cases to minimize off-target effects. Expression of PKCe was reduced >75% by either sequence without any noticeable change in the levels of the other DAG-responsive PKCs present in these cells (PKCa and PKCd) (Figure 1b) . Cell proliferation was significantly reduced in all four NSCLC cell lines in which PKCe was stably depleted (Figure 1c) . Moreover, assays of colony formation in liquid and semisolid medium revealed that both anchorage-independent and anchorage-dependent growth were impaired in PKCedepleted H358 cells relative to control cells. Similar results were observed in A549 cells (Figures 1d and e) . These data suggest that PKCe may be important in NSCLC growth.
PKCe depletion inhibits NSCLC xenograft growth
In order to assess the effect of PKCe depletion on the tumorigenic potential of NSCLC cells in vivo, we injected H358 cell lines stably expressing either e#1 shRNA, e#2 shRNA or control shRNA subcutaneously into athymic nude mice. Inoculation of control H358 cells led to the formation of tumors with a latency of B2 weeks. Notably, tumor growth of PKCe-depleted cells was remarkably lower compared with control NSCLC cells (Figure 2a) . Inhibition of tumor growth was more evident in NSCLC cells expressing shRNA e#1, which shows near complete depletion of PKCe. Immunohistochemical analysis of xenografts 15 days after inoculation showed a marked induction of cell death in PKCedepleted cells, as evidenced by a large number of TUNEL-positive cells (Figure 2b ).
Pharmacological inhibition of PKCe impairs NSCLC tumor growth PKC isozymes have been extensively studied as therapeutic targets, and several modulators of PKC activity have been examined in clinical trials for multiple malignancies (Barry and Kazanietz, 2001; Goekjian and Jirousek, 2001; Serova et al., 2006) . Surprisingly, despite the established relevance of PKCe in mitogenesis and survival, there are no studies to date examining PKCe as a potential therapeutic target for lung cancer. This may be partly due to the lack of kinase inhibitors with selectivity toward PKCe. Indeed, most ATPbinding site-directed inhibitors fail to discriminate between PKC isozymes and/or have additional kinases as targets (Mochly-Rosen and Kauvar, 1998; Davies et al., 2000; Bain et al., 2003 Bain et al., , 2007 . We decided to take advantage of eV1-2, a peptide that specifically inhibits PKCe translocation without affecting the activation of other PKC isozymes (Begley et al., 2004; Felber et al., 2007) . This PKCe inhibitor has been successfully delivered as a TAT-fused protein into cellular models as well as into mice and rats (Gray et al., 1997; Inagaki et al., 2005; Budas et al., 2007; Koyanagi et al., 2007) .
H358 xenografts were implanted subcutaneously in athymic mice, and when tumors reached B100 mm 3 , animals were randomized into two groups that received either eV1-2 conjugated to TAT or control TAT (18 mg/ kg/day) by osmotic minipumps. Previous studies have found that administration of eV1-2 for 5 weeks at 20 mg/kg/day does not cause cytotoxic or systemic effects to mice . Osmotic minipumps were replaced every 7 days and tumor growth was followed for 3 weeks. As shown in Figure 2c , delivery of eV1-2 into nude mice greatly reduced H358 xenograft growth. Immunohistochemical analysis showed a strong induction of cell death (TUNEL-positive cells) in tumors from mice that received eV1-2. On the other hand, there were essentially no TUNEL-positive cells in tumors from animals that received the control TAT peptide (Figure 2d ). These results strongly argue for a role for PKCe in NSCLC tumor cell survival.
Identification of PKCe target genes related to survival in NSCLC cells and tumors
In a recent genome-wide analysis, we established that individual members of the PKC family differentially modulate gene expression. PKCe-regulated gene sets related to cell cycle, K-Ras oncogenesis, and transformation were identified (Caino et al., 2011) . Given that PKCe loss-of-function induces cell death in NSCLC xenografts, we sought to determine whether PKCe regulates the expression of apoptotic/survival genes. ) were seeded in 12-well plates, allowed to grow in 2% fetal bovine serum and counted 48 h later using a hemocytometer. (d) For liquid colony formation assays, cells were plated in 100 mm plates (100 cells/plate for H358 and 1000 cells/plate for A549). Medium was replaced twice a week, and after 15 days colonies were stained with 0.7% methylene blue in 50% ethanol. (e) To evaluate anchorage-independent growth, 3 Â 10 3 cells were plated in 0.35% agar over a 0.5% agar layer. After 10 days, the plates were stained with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). For each well, the number of colonies was counted in five different fields and averaged. In all cases, data are expressed as mean±s.e.m. of three individual experiments. *Po0.05; **Po0.01; ***Po0.001.
Using a Human Apoptosis array (QIAGEN, Valencia, CA, USA), we compared the mRNA levels of key apoptosis-related genes in control vs PKCe-depleted cells. A 1.5-fold cutoff value (PKCe/control) was used. This analysis revealed that PKCe depletion increased mRNA levels of pro-apoptotic proteins Bak1, Bcl2A1, Bcl2L10, Bik and HRK (Table 1) . PKCe depletion was associated with a significant decrease in the expression of the pro-survival protein Bcl-2 and the inhibitor of apoptosis cIAP-2 (Figure 3a and data not shown). In addition, PKCe-depleted cells expressed higher levels of caspase recruitment domain (CARD)-containing proteins (Bag4, CARD8) and caspases (CASP2, CASP3, CASP4 and CASP6) relative to control cells. Several ligands and receptors of the tumor necrosis factor superfamily were also elevated as a consequence of PKCe depletion (Table 1) . In order to validate the results from the array, 11 genes were selected. Figure 3a shows that in all cases the changes observed in the array could be recapitulated using real-time quantitative PCR. Several of these genes were further validated by western blot (Figure 3b ). These results suggest that PKCe has an important role in the modulation of genes involved in cell survival and raise the possibility that they contribute to the susceptibility to apoptosis upon PKCe depletion.
To further investigate the relevance of PKCe target genes in NSCLC, we carried out a comprehensive analysis of publicly available human lung cancer datasets. A comparison of PKCe mRNA levels in human lung adenocarcinomas (LAC) vs normal lung (NL) tissue using the Oncomine repository revealed marked upregulation in LAC (fold change ¼ 2.5, Po0.05, Beer Lung study). Remarkably, the vast majority of the genes with expression altered in PKCedepleted cells were deregulated in LAC (Table 1 and  Supplementary Tables S1-S2 ). As expected, pro-apoptotic genes upregulated in PKCe-depleted cells were downregulated in LAC, whereas pro-survival genes downregulated in PKCe-depleted cells were upregulated in LAC. Furthermore, a meta-analysis from all available studies for each gene revealed that expression changes in LAC vs NL were statistically significant for 27 of the Abbrevitions: CTRL, short-hairpin RNA (shRNA) control; GSEA, Gene Set Enrichment Analysis; NA, not applicable; NS, not significant; NSCLC, non-small cell lung carcinoma; PKC, Protein kinase C; qPCR, real-time quantitative PCR. Simultaneous detection of apoptosis-related genes and two housekeeping genes by qPCR was carried out using RT 2 Profiler PCR Array plates (QIAGEN) and a RT 2 SYBR Green/5-carboxy-X-rhodamine (ROX) qPCR master mix. Data were normalized to GAPDH and b-actin housekeeping genes, and the relative levels of mRNA calculated according to the DCt method. Genes that changed expression >1.5-fold as a consequence of PKCe depletion were selected for further analysis. Tumor cells, H358 cells expressing CTRL or shRNA for PKCe (e#1 and e#2) were assayed for expression of key apoptosis-related genes. Human samples, data publicly available from the Oncomine repository. Lung adenocarcinomas (LAC) were compared against normal lung tissues (NL). Data for each gene were filtered for downregulation in LAC vs NL tissue with a Po0.05. Whenever possible, multiple studies containing information for each gene were compared by meta-analysis, and an associated P-value was determined. P-values for single gene (Single) or meta-analysis (Meta) are shown. To establish if PKCe-regulated genes are altered in lung cancer, we carried out a GSEA, as previously described (Subramanian et al., 2005) . A GSEA comparing LAC (n ¼ 139) vs NL (n ¼ 17) was run for the defined PKCe gene set using the complete dataset for the Bhattacharjee Study (Bhattacharjee et al., 2001) . Enrichment in NL is indicated by 'Yes'.
PKCe-regulated genes (21 genes downregulated and 6 genes upregulated in LAC) ( Table 1) . Based on these results, we defined a set for genes regulated negatively by PKCe that passed the threshold of statistical significance Po0.05 that we named 'PKCe-gene set'.
In order to gain biological insight from these gene expression studies and determining a potential correlation between the expression of PKCe-regulated genes and disease status, we carried out a Gene Set Enrichment Analysis using as a query the above-defined PKCe gene set. Interestingly, a significant correlation was found between downregulation of PKCe-regulated genes and LAC samples (Po1 Â 10 À8 and FDR o0.001). Among the genes negatively correlated with LAC (enrichment score, ESo0), we found FAS, CASP4, CD40, BIRC2, CASP1, TRAIL (TNFSF10), MCL1 and BNIP3 L (Table 1, GSEA column). In summary, this analysis identified novel apoptosis-related PKCe transcriptional targets associated with NSCLC, suggesting an important role for PKCe in the inhibition of pro-apoptotic genes.
Final conclusions
Our studies clearly show that overexpression of PKCe is a key driving force in the growth and tumorigenicity of NSCLC cells. PKCe depletion or pharmacological inhibition reduced tumor growth and enhanced tumor cell death, as demonstrated also in cell models in vitro. A key mechanism by which PKCe may sustain tumorigenicity of NSCLC cells is via modulation of the expression of apoptotic genes. A point that illustrates the relevance of our findings is that the majority of the PKCe apoptotic target genes are downregulated in human NSCLC samples. Moreover, current unpublished studies from our laboratory suggest that PKCe is a key modulator of transcriptional networks of genes that dictate cell fate (MCC and MGK, unpublished observations). Conceivably, targeting PKCe may reinstate altered transcriptional patterns displayed by NSCLC cells that contribute to disease development.
One of the outstanding questions raised by this study is the utility of PKCe as a therapeutic target. Our results suggest that PKCe is required for survival of tumor cells and that PKCe depletion of inhibition is sufficient to inhibit tumor growth of lung cancer cells. Three major issues are raised by these results that required ample investigation. The first is the mechanism that leads to PKCe upregulation in lung cancer (or other epithelial cancers). Preliminary data from our laboratory suggest that deregulation occurs at a transcriptional level and possibly through enhanced protein stability (Wang HB, Lu H and Kazanietz MG, unpublished observations). Second, it remains to be determined whether PKCe has for PKCe (e#1 and e#2) were assayed for expression of key apoptosis-related genes. (a) For real-time quantitative PCR, RNA was isolated using the QIAGEN RNeasy kit and reverse transcribed to cDNA using random hexamers and the TaqMan Reverse Transcription kit (Applied Biosystems, Carlsbad, CA, USA). Real-time PCR assays were performed in a 7300 ABI PCR System (Applied Biosystems), using TaqMan Gene expression assays and TaqMan Universal master mix. Human 18S rRNA was used as an endogenous control for normalization. The relative levels of mRNA compared with control were calculated according to the DCt method. (b) Western blots and the corresponding densitometric analyses were carried out essentially as previously described (Oliva et al., 2008) . The following primary antibodies were used: anti-Bik, anti-Bak, anti-caspase 3, anti-cIAP2, anti-Bcl2, anti-Bcl-XL (Cell Signaling, Danvers, MA, USA, 1:1000 dilution) and anti-b-actin (Sigma, 1:50 000 dilution). Densitometric analysis of three independent experiments is shown. Data are expressed as the mean ± s.e.m. (n ¼ 3). *Po0.05; **Po0.01; ***Po0.001. a role in the initiation of lung cancer and whether its overexpression cooperates with other oncogenic alterations characteristic of the disease. Last, it would be important to establish whether overexpression of PKCe also involves its hyperactivation. Conceivable, oncogenic alterations that occur in lung cancer lead to enhanced generation of DAG, the physiological PKCe activator. For example, mutant K-Ras is known to elevate cellular DAG levels (Fleischman et al., 1986; Preiss et al., 1986; Matyas and Fishman, 1989) . EGFR, which is overexpressed/hyperactivated in 50-90% of human lung tumors (Sekido et al., 2003) , couples to phospholipase Cg, a key enzyme responsible for DAG generation (Rusch et al., 1993; Toker, 1998; Paez et al., 2004; Pao et al., 2004; Parker and Murray-Rust, 2004) . Moreover, EGFR signals to PDK-1, a PIP3-dependent kinase required for the maturation of PKCe (Toker, 1998; Parker and Murray-Rust, 2004) . Both K-Ras and EGFR are established drivers of survival signals (Malumbres and Barbacid, 2003; Lemmon and Schlessinger, 2010) , but the implication of PKCe in these responses remains to be determined. Whether other common oncogenic alterations in lung cancer, such as bFGF and VEGF overexpression, or PI3 K, p53 and Pten mutations (Sekido et al., 2003) , lead to PKCe activation needs to be established. Our data therefore warrant the analysis of signals leading to PKCe activation and upregulation in lung cancer cells. Dissecting these mechanisms may help determining the potential of PKCe as a therapeutic target for different subsets of lung cancers or establish new regimens of combined therapy.
